Amlexanox vs Semaglutide
Research Verdict
Semaglutide is the stronger research reference for the stated comparison criteria. Semaglutide: FDA approved (Wegovy/Ozempic), STEP-1 trial (Wilding et al.
Quick Answers
Which is better, Amlexanox or Semaglutide?
Semaglutide is the stronger research reference for the stated comparison criteria. Semaglutide: FDA approved (Wegovy/Ozempic), STEP-1 trial (Wilding et al.
What is the key difference between Amlexanox and Semaglutide?
Semaglutide has the largest and most rigorous obesity/cardiometabolic dataset of any anti-obesity medication; amlexanox represents early-stage exploration of a different metabolic pathway (IKKe/TBK1 inhibition) that has not progressed beyond pilot testing.
Evidence Comparison
Semaglutide: FDA approved (Wegovy/Ozempic), STEP-1 trial (Wilding et al. NEJM 2021, n=1,961) showing 14.9% weight loss, SELECT CVOT (n=17,604) showing 20% MACE reduction. Amlexanox: one pilot study (n=42) with modest metabolic effects. The evidence gap is enormous.
Evidence Context Favoring Amlexanox
Basic research into IKKe/TBK1 inflammatory metabolism, not as a therapeutic comparator to semaglutide.
Evidence Context Favoring Semaglutide
Any metabolic, weight loss, or cardiometabolic research - semaglutide has the strongest evidence base in its class.
Side-by-Side Snapshot
| Evidence grade | Amlexanox: Level C Semaglutide: Level A |
|---|---|
| Research status | Amlexanox: Phase 2 Semaglutide: FDA Approved |
| Primary category | Amlexanox: Weight Loss & Metabolic Semaglutide: Weight Loss & Metabolic |
| Cited studies | Amlexanox: 2 Semaglutide: 6 |